3Bonadonna G,Brusamolion E,Valagussa P,et al.Combination chemotherapy as an adjuvant treatment in operable breast cancer[J].N Engl J Med,1976,294:405 -410.
4Bonadonna G,Moliterni A,Zambetti M,et al.30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer[J].cohort study.BMJ,2005,330:217 -220
5Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21 (6):976 -983.
6Mamounas EP,Bryant J,Lembersky BC,et al.paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer.Results from NSABP B-28[J].Proc Am Soc Clin Oncol,2003,22:12A(Abstr 12).
7Jean-Marc Nabholtz,Tadeuz Pienkowski,John Mackey,et al.Phase Ⅲ trial comparing TAC (docetaxel,doxorubicin,cyclophsphamide) with FAC (5-fluorouracil,doxorubicin,cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients:interim analysis of the BCIRG 001 study[J].Proc Am Soc Clin Oncol,2002,21:36a (Abstr 141).
8ATAC Trialists' Group.Results of the ATAC (Arimidex,Tamoxifen,Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer[J].Lancet,2005,365(9453):60 -62.
9Goss PE,Ingle JN,Martino S,et at Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing five years oftamoxifen[J].Breast Cancer Res Treat,2003,82 (supple l):abstr 42.
10Fricker J.Letrozole better than tamoxifen in postmenopausal women[J].Lancet Oncol,2005,6:137.
3Robbins GF,Bross I. The significance of delay in re-lation to prognosis of patients with primary operablebreast cancer[J]. Cancer, 1957,10(2) :338-344.
4Wilkinson GS,Edgerton F,Wallace J,et al. Delay,stage of disease and survival from breast cancer[J]. JChronic Dis,1979,32(5) :365-373.
5Harirchi I,Ghaemmaghami F,Karbakhsh M,et al.Patient delay in women presenting with advancedbreast cancer: an Iranian study[J]. Public Health,2005,119(3):885-891.
6Hansen RP,Olesen F,Srensen HT,et al. Socioeco-nomic patient characteristics predict delay in cancerdiagnosis: a danish cohort study [J]. BMC HealthServ Res,2008,28(8) :49-58.
7Elwood JM, Moorehead WP. Delay in diagnosis andlong-term survival in breast cancer [J]. BMJ,1980,280(6227):1291-1294.
8Richards MA,Westcombe AM, Love SB, et al. In-fluence of delay on survival in patients with breastcancer : a systematic review [ J ]. Lancet,1999,353(9159) :1119-1126.
9Berrino F,De Angelis R,Sant M,et al. Survival foreight major cancers and all cancers combined for Eu-ropean adults diagnosed in 1995-1999 : results of EU-ROCARE-4 study[J]. Lancet Oncopgy,2007,8 (9):773-783.
10Sant MA, Aareleid T, Berrino F,et al. EUROCARE-3: survival of cancer patients diagnosed 1990-1994—re-sults and commentary [J ]. Ann Oncol,2003,14 (Suppl5):61-118.
